American Journal of Cardiology
Volume 108, Issue 3 , Pages 360-366 , 1 August 2011

Relation of Increased Prebeta-1 High-Density Lipoprotein Levels to Risk of Coronary Heart Disease

  • Lin T. Guey, PhD

      Affiliations

    • Applied Quantitative Genotherapeutics, Pfizer Pharmaceuticals, Cambridge, Massachusetts
    • ,
  • Clive R. Pullinger, PhD

      Affiliations

    • Cardiovascular Research Institute, University of California, San Francisco, San Francisco, California
    • ,
  • Brian Y. Ishida, PhD

      Affiliations

    • Cardiovascular Research Institute, University of California, San Francisco, San Francisco, California
    • ,
  • Patricia M. O'Connor, MD

      Affiliations

    • University of Limerick, Limerick, Ireland
    • ,
  • Christian Zellner, MD

      Affiliations

    • Cardiovascular Research Institute, University of California, San Francisco, San Francisco, California
    • ,
  • Omar L. Francone, PhD

      Affiliations

    • Cardiovascular, Metabolic and Endocrine Diseases, Pfizer Pharmaceuticals, Groton, Connecticut
    • ,
  • Jason M. Laramie, PhD

      Affiliations

    • Applied Quantitative Genotherapeutics, Pfizer Pharmaceuticals, Cambridge, Massachusetts
    • ,
  • Josefina M. Naya-Vigne, MD

      Affiliations

    • Cardiovascular Research Institute, University of California, San Francisco, San Francisco, California
    • ,
  • Ketevan A. Siradze, MD

      Affiliations

    • Genentech, Inc., South San Francisco, California
    • ,
  • Prakash Deedwania, MD

      Affiliations

    • Veterans Affairs Central California Health Care System/UCSF, Fresno, California
    • ,
  • Rita F. Redberg, MD

      Affiliations

    • Department of Medicine, University of California, San Francisco, San Francisco, California
    • ,
  • Philip H. Frost, MD

      Affiliations

    • Department of Medicine, University of California, San Francisco, San Francisco, California
    • ,
  • Albert B. Seymour, PhD

      Affiliations

    • Applied Quantitative Genotherapeutics, Pfizer Pharmaceuticals, Cambridge, Massachusetts
    • ,
  • John P. Kane, MD, PhD

      Affiliations

    • Cardiovascular Research Institute, University of California, San Francisco, San Francisco, California
    • ,
  • Mary J. Malloy, MD

      Affiliations

    • Cardiovascular Research Institute, University of California, San Francisco, San Francisco, California
    • Corresponding Author InformationCorresponding author: Tel: 415-476-2754; fax: 415-502-5658

Received 12 January 2011 ,Revised 18 March 2011 ,Accepted 18 March 2011.

Title About Type File Size
Supplementary Material Other 0 MB

Please note that add-on components may require plug-in applications.

 This work was supported in part by Grants HL3120, HL50782, Hl50779, and AA11205 from the National Institutes of Health, Bethesda, Maryland; Foundation Leducq, Paris, France; Campini Foundation, San Francisco, California; Joseph Drown Foundation, Los Angeles, California; and a gift from Donald Yellon, San Francisco, California.

PII: S0002-9149(11)01349-X

doi: 10.1016/j.amjcard.2011.03.054

American Journal of Cardiology
Volume 108, Issue 3 , Pages 360-366 , 1 August 2011

Article Tools

* Image Usage & Resolution